2025-04-08 17:34:59
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Marksans Pharma Ltd consolidated Q2FY22 net profit slips to Rs. 46.28 crore
Posted On : 2021-11-10 12:11:04( TIMEZONE : IST )
Marksans Pharma Limited has reported Consolidated financial results for the period ended September 30, 2021.
Financial Results (Q2 FY2022) - QoQ Comparison
The company has reported total income of Rs. 369.768 crores during the period ended September 30, 2021 as compared to Rs. 354.846 crores during the period ended June 30, 2021.
The company has posted net profit / (loss) of Rs. 46.288 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs. 62.60 crores for the period ended June 30, 2021.
The company has reported EPS of Rs. 1.11 for the period ended September 30, 2021 as compared to Rs. 1.51 for the period ended June 30, 2021.
| Financials | Q2 FY2022 | Q1 FY2022 | % Change |
| Total Income | ₹ 369.768 crs | ₹354.846 crs |  4.21% |
| Net Profit | ₹46.288 crs | ₹62.60 crs |  -26.06% |
| EPS | ₹1.11 | ₹1.51 | -26.49% |
Financial Results (Q2 FY2022) - YoY Comparison
The company has reported total income of Rs. 369.768 crores during the period ended September 30, 2021 as compared to Rs.360.137 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.46.288 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs.50.734 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.1.11 for the period ended September 30, 2021 as compared to Rs.1.21 for the period ended September 30, 2020.
| Financials | Q2 FY2022 | Q2 FY2021 | % Change |
| Total Income | ₹ 369.768 crs | ₹360.137 crs | 2.67% |
| Net Profit | ₹46.288 crs | ₹50.734 crs | -8.76% |
| EPS | ₹1.11 | ₹1.21 | -8.26% |
Financial Results (Half Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.724.615 crores during the 6 Months period ended September 30, 2021 as compared to Rs.691.471 crores during the 6 Months period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.108.891 crores for the 6 Months period ended September 30, 2021 as against net profit / (loss) of Rs.100.099 crores for the 6 Months period ended September 30, 2020.
The company has reported EPS of Rs.2.62 for the 6 Months period ended September 30, 2021 as compared to Rs.2.41 for the 6 Months period ended September 30, 2020.
| Financials | Half Year Ended FY2022 | Half Year Ended FY2021 | % Change |
| Total Income | ₹724.615 crs | ₹691.471 crs | 4.79% |
| Net Profit | ₹108.891 crs | ₹100.099 crs | 8.78% |
| EPS | ₹2.62 | ₹2.41 | 8.71% |
Shares of Marksans Pharma Limited was last trading in BSE at Rs. 67.35 as compared to the previous close of Rs. 66.35. The total number of shares traded during the day was 175313 in over 1909 trades.
The stock hit an intraday high of Rs. 68.20 and intraday low of 66.30. The net turnover during the day was Rs. 11792348.00.
